Skip to main content

Table 1 Baseline characteristics of patients in the modified intention-to-treat (MITT) population

From: Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial

 CTRX (n = 124)ABPC/SBT (n = 139)p-value
Male/female, n (% male)63/61 (51)80/59 (58)0.32*
Age, y60.6 ± 21.363.4 ± 18.40.25
Comorbidities
 Cancer10 (8)14 (10)0.67*
 Hematological malignancy2 (2)0 (0)0.22
 Cardiovascular disease8 (6)14 (10)0.37*
 Chronic lung disease23 (19)24 (17)0.87*
 Bronchial asthma11 (9)13 (9)1.00*
 COPD7 (6)8 (6)1.00*
 Chronic liver disease2 (2)1 (1)0.60
 Chronic kidney disease3 (2)2 (1)0.67
Pneumonia severity index67.8 ± 32.670.7 ± 27.50.45
 Class I, n (%)29 (23)24 (17)0.71
 Class II, n (%)40 (32)47 (34)
 Class III, n (%)25 (20)44 (32)
 Class IV, n (%)24 (19)20 (14)
 Class V, n (%)6 (5)4 (3)
Performance status, n (%)
 0108 (87)122 (88)0.87
 111 (9)12 (9)
 24 (3)2 (1)
 30 (0)2 (2)
 41 (1)1 (1)
Maximum body temperature, °C
 Before treatment38.1 ± 0.838.1 ± 1.00.89
 Day of visit38.0 ± 0.838.0 ± 1.00.79
Systolic blood pressure, mmHg127.8 ± 21.5131.4 ± 24.80.22
Diastolic blood pressure, mmHg73.0 ± 15.973.1 ± 13.10.97
Pulse rate, beats/min90.3 ± 16.789.0 ± 14.90.49
Respiration rate, breaths/min (n)21.2 ± 4.6 (83 cases)22.2 ± 5.5 (99 cases)0.18
CRP, mg/dL10.7 ± 7.212.9 ± 7.70.02
WBC, ×103/μL11.6 ± 5.211.3 ± 5.60.60
Albumin, g/dL (n)3.8 ± 0.5 (123 cases)3.7 ± 0.4 (137 cases)0.42
  1. CTRX Ceftriaxone, ABPC/SBT Ampicillin/sulbactam, CRP C-reactive protein, WBC White blood cell. Data are presented as mean ± standard deviation (SD) for continuous variables and number (%) for categorical variables. Comparisons were conducted using Student’s t-test unless otherwise indicated. *Chi-squared test. Fisher’s exact test. Mann-Whitney U test